: Extensive new data on biologics and novel small molecules for treating and preventing IBD recurrences. Obesity Management
: Expanded coverage of eosinophilic disorders, autoimmune liver diseases, and the latest treatments for viral hepatitis. Renamed Conditions : Incorporation of new terminology, such as
covering endoscopic techniques like balloon dilatation and stent placement. Reference Details Elsevier Health Sciences Publication Date 10–15 December 2025 978-0443116575 Page Count Approx. 2,500–3,700 pages (2-Volume Set) Target Audience s gastrointestinal and liver disease 12th edition
This is for informational purposes only. For medical advice or diagnosis, consult a professional. AI responses may include mistakes. Learn more
The 12th edition is far more than a routine update; it is a thorough revision that addresses the most dynamic and impactful areas of modern gastroenterology. The text has been meticulously expanded and enhanced to reflect the rapid pace of discovery and clinical innovation. : Extensive new data on biologics and novel
This edition reflects the significant shifts in gastroenterology over the last several years:
The 12th edition introduces major content and structural updates, focusing on the most pressing areas of modern GI practice: AI responses may include mistakes
| | Key Update in the 12th Edition | | :--- | :--- | | Eosinophilic Esophagitis (EoE) | Updated diagnostic criteria (EoE Histology Scoring System); new therapies including budesonide oral suspension and dupilumab. | | Inflammatory Bowel Disease (IBD) | Comparative efficacy of advanced therapies (JAK inhibitors, anti-IL23, S1P modulators); role of intestinal ultrasound for monitoring. | | Pancreatic Cystic Lesions | Revised Sendai and Fukuoka guidelines; role of molecular markers (KRAS/GNAS mutations) in cyst fluid. | | Celiac Disease | Novel serologic markers (deamidated gliadin peptides); management of non-responsive celiac disease; potential for lanrazenotide. | | Colorectal Cancer Screening | USPSTF updated age to 45; role of multitarget stool DNA (Cologuard) and blood-based tests (Shield); post-polypectomy surveillance intervals. |
The 12th edition is packed with significant updates, new chapters, and expanded discussions that reflect the latest advancements in gastroenterology and hepatology. The text has been meticulously revised to present everything from basic science to the newest techniques and technologies. Key new features and discussions include:
Sleisenger and Fordtran's Gastrointestinal and Liver Disease